Sign in
Taking people in FrancePhase 3

Light therapy and melatonin for depression with sleep problems

Tests light therapy and melatonin, alone or together, in adults with depression and insomnia.

Key facts

Who runs it
Assistance Publique Hopitaux De Paris
Where
Lille, Paris, Paris Cedex 13, Paris Cedex 18, and Strasbourg, FranceSee the 5 sites
Registry title
CombiChronoS - Effectiveness of a Combination of Chronotherapeutics for the Treatment of Major Depressive Episode (MDE) with Insomnia: A Multicenter, Randomized, Double-Blind, Placebo-Controlled 2x2 Factorial Trial
Status
Recruiting
Phase
Phase 3
People taking part
184 people, planned
Started
28 Jan 2026
Expected to end
1 Sept 2027
Type of study
Interventional
Record updated
12 May 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with a major depressive episode (unipolar depression) who also have insomnia. It tests light therapy and 2 mg prolonged-release melatonin, alone or together, for 8 weeks.

Age
18 to 65 years in the criteria; the record's age fields say 18 to 64 years.
Sex
All sexes can join.
Disease stage
Major depressive episode in unipolar disorder (DSM-5), at least moderate, with a MADRS score ≥20. Insomnia (DSM-5) with an ISI score ≥8. Outpatient or inpatient care for 8 weeks.
Earlier treatment
No antidepressants of any kind in the month before joining. No light therapy in the month before joining. No melatonin at the time of joining.

Main reasons for not taking part

  • Eye diseases or diseases that affect the retina, such as cataracts, glaucoma or diabetes.
  • Schizophrenia, other psychotic disorders, bipolar disorder (YMRS score ≥ 12), or unstable substance use including alcohol and tobacco.
  • Depression that did not respond to 2 antidepressants from different classes.
  • High suicide risk (C-SSRS score ≥ 4).
  • Pregnant or breastfeeding women.

The registry criteria, word for word

Show all 19 criteriaShow less

Who can take part

  • 1-Aged 18 to 65 years
  • 2- Diagnosed with Major Depressive Episode (MDE) in the context of a unipolar disorder (DSM-5 criteria) and a MADRS score ≥20 (threshold validated for moderate MDE)
  • 3- Comorbid insomnia (DSM-5 criteria) with an ISI score ≥8 (threshold validated for mild and clinically significant insomnia)
  • 4- Not exposed to antidepressants of any class in the month prior to inclusion
  • 5- Not exposed to light therapy in the month prior to inclusion
  • 6- Patients receiving outpatient or inpatient care for a treatment duration of 8 weeks
  • 7- Ability to understand and sign the informed consent

Who cannot take part

  • 12- Contraindication to selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors (SNRIs)
  • 9- Treatment with melatonin at the time of inclusion
  • 11- Known hypersensitivity to melatonin
  • 3- The following disorders (according to DSM-5): Schizophrenia and other psychotic disorders; Bipolar disorder, particularly (hypo)manic episodes (YMRS score ≥ 12); Other unstable mental disorders, such as substance use disorders, including alcohol and tobacco
  • 4- Other unstable general medical conditions
  • 2- Ophthalmic diseases (cataracts, glaucoma, age-related macular degeneration, etc.) or diseases affecting the retina (retinitis pigmentosa, diabetes, herpes, etc.)
  • 1- Subjects under guardianship or deprived of liberty
  • 10- Participation in another interventional study during the course of the trial
  • 5- Pregnant or breastfeeding women
  • 6- Hypersomnia with prolonged total sleep time secondary to MDE according to ICSD-3 criteria
  • 7- Therapeutic resistance of the current MDE (2 antidepressants from different classes)
  • 8- Presence of a high suicide risk, assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS, score ≥ 4)

The main criteria, as questions

These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Are you between 18 and 64 years old?

This trial is currently available in France.

  • Centre Hospitalier Universitaire de LilleLille, FranceTaking people
  • Groupe Hospitalier Universitaire Paris Psychiatrie Et NeuroscienceParis, FranceTaking people
  • Assistance Publique Hopitaux De ParisParis Cedex 13, FranceTaking people
  • Assistance Publique Hopitaux De ParisParis Cedex 18, FranceTaking people
  • Alentis DevelopmentStrasbourg, FranceTaking people

About the trial

What the trial wants to find out

To evaluate the effectiveness of two chronotherapeutics, either alone or in combination, on the reduction of depressive symptoms after 8 weeks of treatment in patients with Major Depressive Episode (MDE): active light therapy for 8 weeks and 2 mg prolonged-release melatonin for 8 weeks.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
CombiChronoS - Effectiveness of a Combination of Chronotherapeutics for the Treatment of Major Depressive Episode (MDE) with Insomnia: A Multicenter, Randomized, Double-Blind, Placebo-Controlled 2x2 Factorial Trial
Plain-language title
Light therapy and melatonin for depression with sleep problemsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Criteria questions
Built from 2024-516371-32-00, who can take part
Record updated
12 May 2025